DK2875355T3 - Modulation af sapp-, sapp-alpha- og bdnf-niveauer hos individeer diagnosticeret med fxs og asd - Google Patents

Modulation af sapp-, sapp-alpha- og bdnf-niveauer hos individeer diagnosticeret med fxs og asd Download PDF

Info

Publication number
DK2875355T3
DK2875355T3 DK13823641.9T DK13823641T DK2875355T3 DK 2875355 T3 DK2875355 T3 DK 2875355T3 DK 13823641 T DK13823641 T DK 13823641T DK 2875355 T3 DK2875355 T3 DK 2875355T3
Authority
DK
Denmark
Prior art keywords
sapp
diagnosticated
fxs
asd
individuals
Prior art date
Application number
DK13823641.9T
Other languages
English (en)
Inventor
Craig A Erickson
Debomoy K Lahiri
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Application granted granted Critical
Publication of DK2875355T3 publication Critical patent/DK2875355T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/48Nerve growth factor [NGF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK13823641.9T 2012-07-22 2013-07-22 Modulation af sapp-, sapp-alpha- og bdnf-niveauer hos individeer diagnosticeret med fxs og asd DK2875355T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261674367P 2012-07-22 2012-07-22
US201261675116P 2012-07-24 2012-07-24
US201361748652P 2013-01-03 2013-01-03
PCT/US2013/051550 WO2014018468A1 (en) 2012-07-22 2013-07-22 Modulation sapp, sapp alpha and bdnf levels in individuals diagnosed with fxs and asd

Publications (1)

Publication Number Publication Date
DK2875355T3 true DK2875355T3 (da) 2020-03-02

Family

ID=49997763

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13823641.9T DK2875355T3 (da) 2012-07-22 2013-07-22 Modulation af sapp-, sapp-alpha- og bdnf-niveauer hos individeer diagnosticeret med fxs og asd

Country Status (8)

Country Link
US (1) US9770423B2 (da)
EP (1) EP2875355B1 (da)
JP (1) JP6548575B2 (da)
AU (1) AU2013293167B2 (da)
CA (1) CA2879113C (da)
DK (1) DK2875355T3 (da)
RU (1) RU2675252C2 (da)
WO (1) WO2014018468A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3058371T (pt) 2013-10-14 2021-07-26 Univ Indiana Res & Tech Corp Uso de acamprosato para modular a ativação de erk 1-2 em modelos animais de sxf e tea e indivíduos diagnosticados com sxf e tea
WO2017147044A1 (en) * 2016-02-22 2017-08-31 Indiana University Research And Technology Corporation Peptides and methods for treatment of neurodegenerative diseases
EP3624788A4 (en) 2017-05-17 2021-03-03 Confluence Pharmaceuticals, LLC FORMULATIONS OF HOMOTAURINS AND THEIR SALTS
WO2019025931A1 (en) 2017-07-31 2019-02-07 Novartis Ag USE OF A MUSSEL FOR REDUCING THE USE OF COCAINE OR FOR PREVENTING A RECHUTE IN THE USE OF COCAINE
KR20200035262A (ko) * 2017-07-31 2020-04-02 노파르티스 아게 알코올 사용 감소 또는 알코올 사용 재발 예방에 있어서 마보글루란트의 용도
CN110240599A (zh) * 2018-03-07 2019-09-17 齐鲁制药有限公司 一种利格列汀杂质及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ324615A (en) 1996-03-11 2000-08-25 Lilly Co Eli Method for treating autism using olanzapine
ATE518540T1 (de) 1999-08-16 2011-08-15 Revaax Pharmaceuticals Llc Beta-lactam verbindung enthaltende neurotherapeutische zusammensetzung
SE0300586L (sv) 2003-03-04 2004-09-05 Forskarpatent I Syd Ab Diagnos av autism
US20080139472A1 (en) 2006-10-06 2008-06-12 The Regents Of The University Of California Upregulating bdnf levels to mitigate mental retardation
US20090239888A1 (en) * 2008-02-12 2009-09-24 Wisconsin Alumni Research Foundation Methods for Inhibiting Amyloid Precursor Protein and Beta-Amyloid Production and Accumulation
JP5688035B2 (ja) 2009-02-12 2015-03-25 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 合併性および特発性自閉症を含む発達障害を治療するための物質および方法
US8008539B1 (en) 2009-03-19 2011-08-30 University Of South Florida Generation of transgenic human soluble amyloid precursor protein alpha expressing mice
US20110294879A1 (en) * 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
CA2808660A1 (en) 2010-08-19 2012-02-23 Blanchette Rockefeller Neurosciences Institute Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators

Also Published As

Publication number Publication date
AU2013293167B2 (en) 2019-04-18
RU2675252C2 (ru) 2018-12-18
US9770423B2 (en) 2017-09-26
CA2879113C (en) 2021-11-16
US20150209312A1 (en) 2015-07-30
AU2013293167A1 (en) 2015-02-12
EP2875355B1 (en) 2020-02-05
JP6548575B2 (ja) 2019-07-24
EP2875355A1 (en) 2015-05-27
EP2875355A4 (en) 2016-08-03
JP2015524805A (ja) 2015-08-27
CA2879113A1 (en) 2014-01-30
RU2015105947A (ru) 2016-09-20
WO2014018468A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
DK3090068T3 (da) Fremgangsmåde og kit til ikke-invasiv detektering af egfr-genmutationer
DK2764084T4 (da) Anvendelse af phosphoketolase i fremstillingen af mevalonat, isoprenoid-udgangsstoffer, og isopren
DK2882496T3 (da) Behandling og diagnosticering af melanom
DK3252160T3 (da) Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK2890277T3 (da) System, fremgangsmåde og kapsler til fremstilling af drikke med brus
DK2743669T3 (da) Fejldetekteringssystem og tilhørende fremgangsmåde
DK3432649T3 (da) Radionetværksknude, brugerindretning og fremgangsmåder dertil
DK2804587T3 (da) Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed
DK2943192T3 (da) Fremgangsmåder til behandling af pancreascancer, hvilke fremgangsmåder omfatter paclitaxel og gemcitabin
DK2920313T3 (da) Rekombinante adenovira og anvendelse deraf
DK3339303T3 (da) Kondenserede aryl- og heteroaryllactamer
DK3698630T3 (da) Administration og overvågning af nitrogenoxid i ex vivo fluider
DK2560972T3 (da) Forbindelser og fremgangsmåder til kinasemodulering og indikationer hertil
DK2892912T3 (da) C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
DK2815769T3 (da) Fam19a5 til anvendelse i diagnosticering og behandling af skader på centralnervesystemet
SG11201509373YA (en) Triptycene-based dianhydrides, polyimides, methods of making each, and methods of use
DK2875355T3 (da) Modulation af sapp-, sapp-alpha- og bdnf-niveauer hos individeer diagnosticeret med fxs og asd
DK3242071T3 (da) Belysningsindretning, indsættelses- og modtageelement
DK2585362T3 (da) Forbindelseslåseenhed og fremgangsmåde
DK2805670T3 (da) Forbedringer af og i sammenhæng med oftalmoskoper
SG11201405054PA (en) Amido-benzyl sulfone and sulfoxide derivatives
DK2861273T3 (da) Anvendelse af heparin og kulhydrater til behandling af cancer.
DK2917181T3 (da) Heteroarylderivater og anvendelser deraf
DK3086614T3 (da) Fremgangsmåde og indretning til indikation af in-device coexistence (idc)